ARTEMISININ PROPHYLACTIC EFFECT AGAINST HEPATOCELLULAR CARCINOMA IN SCHISTOSOMA MANSONI AND HEPATITIS C VIRUS CO-INFECTION: A REVIEW | ||||
| Journal of the Egyptian Society of Parasitology | ||||
| Volume 52, Issue 3, December 2022, Page 549-556 PDF (820.83 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/jesp.2022.278385 | ||||
 View on SCiNiTO | ||||
| Author | ||||
| HEND M. HUSSEIN | ||||
| Department of Parasitology, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt | ||||
| Abstract | ||||
| Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is one of the most common leading causes of cancer related deaths. Chronic Schistosoma mansoni and HCV co-infection accelerates the progression of liver disease increasing incidence of early development of HCC. Anti-parasitic rule of artemisinin together with its anti-viral and antitumor effects make this drug a good target for investigation as a prophylaxis against HCC. Molecular Docking and Dynamics Simulation have improved the quality of healthcare studies through providing high quality predictions of in silicon effect of drugs. This review aims to discuss repositioning artemisinin as a prophylactic treatment against development of HCC in patients co infected with Schistosoma mansoni and HCV, pointing out the rule of Molecular docking and dynamics in predicting the rate of success of this drug. | ||||
| Keywords | ||||
| Schistosomiasis; HCV; HCC; Artemisinin; Molecular docking & dynamics simulation | ||||
|
Statistics Article View: 82 PDF Download: 106 |
||||
